Floatz logo

Tricom-Cea

Liver Cancer

Michael Morse, MDvaccinePhase 1Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
65/ 100

Competitive context

112 Active assets in the Liver Cancer cohort.

Asset / SponsorPhaseRating
Bxcl501
Uppsala University Hospital
Phase 4BBB
Inno-206
Shanghai Zhongshan Hospital
Phase 4BB
Eloxatin
Sun Yat-sen University
Phase 3BB
Hepatitis B Virus Vaccine
Eunice Dube
Phase 4BB
Tranexamic Acid
Konkuk University Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

Tricom-Cea is also rated in:

testicular germ cell tumorDormant
CC
Indicative ·
47 / 100
View asset →
gallbladder cancerDormant
CC
Indicative ·
47 / 100
View asset →
head and neck cancerDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →